retatrutide gip glp-1 glucagon receptor agonist Science Behind GLP 1 and Agonists for Obesity Research | News & Announcements Glucagon-like peptide-1 receptor: mechanisms and

The most important and most frequently used indication for DPP-4 inhibitors is their add-on use in patients who are not sufficiently controlled on metformin monotherapy ( DPP-4 inhibitors can be administered in patients with impaired kidney function due to the good safety and tolerability

Obes Rev 2024

It targets GLP1, GIP, and glucagon receptors simultaneouslyhence the third generation label after single (Ozempic) and dual (Mounjaro) agonists

10,11,12 Multiple studies have found that the BMD of AN patients in the active phase is lower than that of healthy controls, with a decrease of 16% in the lumbar spine, 18% in the femoral neck, and 23% in the total hip